Payment overview · 2025
General Payments
$113.76
6 reported records · 5 companies
Healthcare provider profile · identity verified
Derrick L. Hasenour, MD
Allopathic & Osteopathic Physicians|Family Medicine · FRANKLIN, IN · NPI 1295997450
Verified facts
What the public records show
CMS Open Payments records show Derrick L. Hasenour, MD received $113.76 in general payments during 2025 across 6 reported records.
Exact Sciences Corporation accounted for 31.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.85 | 31.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.87 | 19.2% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $19.02 | 16.7% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.55 | 16.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.47 | 16.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $113.76 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.85 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 221 | 79 |
| Lisinopril | Lisinopril | 198 | 51 |
| Mounjaro | Tirzepatide | 191 | 38 |
| Gabapentin | Gabapentin | 159 | 41 |
| Metformin Hcl | Metformin Hcl | 153 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 136 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 130 | 42 |
| Farxiga | Dapagliflozin Propanediol | 110 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 106 | 31 |
| Ozempic | Semaglutide | 93 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 87 | 26 |
| Montelukast Sodium | Montelukast Sodium | 83 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 81 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 79 | suppressed |
| Losartan Potassium | Losartan Potassium | 77 | 24 |
| Famotidine | Famotidine | 75 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | 18 |
| Omeprazole | Omeprazole | 74 | 29 |
| Alendronate Sodium | Alendronate Sodium | 73 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 30 |
| Jardiance | Empagliflozin | 71 | 22 |
| Prednisone | Prednisone | 67 | 29 |
| Repatha Sureclick | Evolocumab | 54 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 16 |
| Fentanyl | Fentanyl | 51 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 21 |
| Bupropion Xl | Bupropion Hcl | 48 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 43 | 13 |
| Buspirone Hcl | Buspirone Hcl | 41 | 14 |
| Celecoxib | Celecoxib | 39 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 17 |
| Carvedilol | Carvedilol | 37 | 17 |
| Oxycontin | Oxycodone Hcl | 37 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 11 |
| Ezetimibe | Ezetimibe | 36 | 18 |
| Pregabalin | Pregabalin | 34 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Baclofen | Baclofen | 30 | 13 |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | 13 |
| Trazodone Hcl | Trazodone Hcl | 28 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Lubiprostone | Lubiprostone | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Methadone Hcl | Methadone Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 12 |
| Eliquis | Apixaban | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 16 |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 12 |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Furosemide | Furosemide | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $113.76 · 6 records | Exact Sciences Corporation | Auvelity, Cologuard Collection Kit, Fluad, Flucelvax, Ohtuvayre, QULIPTA, UBRELVY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error